The Motley Fool

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November

It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...
Hosted on MSN

Vertex Announces $150 Million Stock Repurchase Program

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex ( (VERX)) has shared an update. On ...
The Business Journals

Vertex taps Microsoft exec as new CEO, replacing longtime leader DeStefano

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...
PE Hub

Wind Point-backed Vertex scoops up healthcare program and project management firm Adams

The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...
Morningstar

VERTEX Expands Healthcare Program Management Capabilities with Acquisition of ADAMS

NEW YORK and ROME, Ga., Aug. 5, 2025 /PRNewswire/ -- The VERTEX Companies, LLC ("VERTEX"), a global professional services firm delivering expert, forensic, construction project advisory, and ...
Investopedia

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
FiercePharma

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Reuters

Vertex's trial failure, scrapped study cloud pain drug push; shares slump

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
Wall Street Journal

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Vertex Pharmaceuticals’VRTX0.29%increase; green up pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...
Bloomberg L.P.

Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
WCVB Channel 5 Boston

5 for Good: Vertex's paid internship benefits Boston students

OF THE AREA MEDIAN INCOME. A GLOBAL BIOTECH COMPANY IS FOSTERING TALENT AMONG BOSTON PUBLIC SCHOOL KIDS. OUR ERIKA TARANTAL REPORTS ON THE PAID INTERNSHIP PROGRAM, GIVING STUDENTS THE OPPORTUNITY OF A ...